graph Evidence gap map comparisons
atezolizumab based treatmentpembrolizumab based treatment
atezolizumab plus nab-paclitaxel atezolizumab plus paclitaxel pembrolizumab plus SoC
mBC - Triple negative (TNBC) - 1st Line (L1) 1
mBC - TNBC - L1 - all population 7       
mBC - TNBC - L1 - PDL1 positive 4        
Comparator:  vs Standard of Care (SoC);   vs placebo plus SoC; 
Risk of bias:  low;   some concerns;   high;  NA;